Home › Funds › Avidity Partners Management LP › KPTI
Avidity Partners Management LP position in KPTI
KARYOPHARM THERAPEUTICS INC · Health Care
Avidity Partners Management LP reported holding 884,900 shares of KPTI (KARYOPHARM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.1M, representing 0.27% of its reported portfolio and ranking #14 among its reported holdings. Avidity Partners Management LP has disclosed KPTI holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Avidity Partners Management LP's KPTI position evolved
Avidity Partners Management LP first disclosed a stake in KPTI in Q3 2023 at 8,298,570 shares (US$11.1M). The position peaked in Q1 2024 at 8,298,570 shares, worth US$12.5M. Across 13 filings, Avidity Partners Management LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 884,900 shares valued at US$1.1M — a reduction of -39,587 shares quarter over quarter.. Notable position changes include a 93% trim in Q1 2025 (shares rose 15% over the following quarter), a 245% increase in Q1 2026 (shares rose 75% over the following quarter), a 99% increase in Q2 2026 (shares fell 88% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 8.30M | $11.12M | New |
| Q4 2023 | 8.30M | $7.18M | Hold |
| Q1 2024 | 8.30M | $12.53M | Hold |
| Q2 2024 | 2.02M | $1.75M | Reduce |
| Q3 2024 | 2.02M | $1.68M | Hold |
| Q4 2024 | 2.02M | $1.37M | Hold |
| Q1 2025 | 134.57K | $503.28K | Reduce |
| Q2 2025 | 134.57K | $579.98K | Hold |
| Q3 2025 | 134.57K | $880.06K | Hold |
| Q4 2025 | 134.57K | $990.41K | Hold |
| Q1 2026 | 463.74K | $2.58M | Add |
| Q2 2026 | 924.49K | $9.03M | Add |
| Q3 2026 | 884.90K | $1.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KPTI and 13F data
KPTI (KARYOPHARM THERAPEUTICS INC) is a Health Care company. 10 other funds we track also report a position in KPTI — the largest reported positions include ACORN CAPITAL ADVISORS, LLC (US$1.5M), Catalio Capital Management, LP (US$1.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KPTI
- ACORN CAPITAL ADVISORS, LLC 1.22M sh · $1.49M · Q3 2026
- Catalio Capital Management, LP 976.19K sh · $1.19M · Q3 2026
More on Avidity Partners Management LP
FAQ
How long has Avidity Partners Management LP held KPTI?
Avidity Partners Management LP has disclosed KPTI holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Avidity Partners Management LP's current position in KPTI?
As of Q3 2026, Avidity Partners Management LP holds 884.90K shares of KPTI (KARYOPHARM THERAPEUTICS INC), valued at $1.08M, representing 0.27% of its reported portfolio and ranking #14.
Has Avidity Partners Management LP been buying or selling KPTI?
In the latest 13F filing (Q3 2026), Avidity Partners Management LP reduced its position in KPTI. The position peaked in Q1 2024 at 8.30M shares.
Which other funds hold KPTI?
Other major institutional holders of KPTI include ACORN CAPITAL ADVISORS, LLC, Catalio Capital Management, LP, among 10 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.